ChatGPT

Perplexity

Gemini

Claude

Grok

A culture of innovation that fosters personal and professional growth, encouraging employees to find pathways for meaningful innovations that make a difference for millions of patients around the world.

Innovation & Excellence

Building diverse, high-performing teams that are engaged and innovative, advancing company culture so that every employee feels valued, respected and safe to be their authentic self.

Diversity, Equity & Inclusion

Prioritizing fairness and leading with empathy and respect, cultivating a culture that is inclusive and caring, built on principles of partnership and trust.

Partnership & Trust

Maintaining high standards of accountability across all operations, ensuring quality and safety in every product that saves and sustains lives.

Accountability

Through the Baxter International Foundation, supporting communities with scholarship programs for employees' children, matching gift programs up to $5,000, and Dollars for Doers converting volunteer time into grants.

Community Impact

Baxter International is a global medical technology company that develops, manufactures, and commercializes healthcare products and digital health solutions, specializing in IV solutions, infusion systems, renal care, and surgical products.

Andrew Hider

President and Chief Executive Officer (Effective September 2025)

Brent Shafer

Chairman and Interim Chief Executive Officer

Heather Knight

Executive Vice President, Chief Operating Officer, and Interim President - Medical Products & Therapies

Joel Grade

Executive Vice President and Chief Financial Officer

Charles Patel

Chief Information Officer and Senior Vice President

Tobi Karchmer

Senior Vice President, Chief Medical Officer, Chief Scientific Officer

Baxter is one of the world's leading manufacturers of commercially prepared IV solutions in flexible containers, providing a broad portfolio of IV fluids to help meet healthcare system needs for commonly prescribed medications and hydration therapy.

IV Solutions and Fluid Delivery

Industry-leading smart infusion pump that revolutionizes integrated pump technology with superior drug library compliance and ease of use, ensuring safe and accurate medication delivery at the bedside.

Spectrum IQ Infusion System

Comprehensive portfolio of peritoneal dialysis and hemodialysis therapies and services, pioneering innovation in renal care to help achieve better outcomes for patients with chronic kidney disease.

Dialysis Products and Services

Leading Parenteral Nutrition Portfolio offering pharmacy technology, premixes and a comprehensive selection of macro and micronutrients to support specific nutritional requirements for critically ill patients.

Parenteral Nutrition Solutions

Technologies designed to enhance surgeons' technique, increase efficiencies and improve patient outcomes, including hemostats, sealants, and adhesion prevention products.

Advanced Surgery Products

Innovative fluid management monitoring system that helps clinicians optimize fluid therapy and improve patient outcomes through real-time hemodynamic monitoring.

Starling Fluid Management Monitoring System

Following the 1998 acquisition of Ohmeda's Pharmaceutical Products Division, Baxter became a leader in inhaled anesthetics for surgical procedures.

Inhaled Anesthetics

Baxter International announced the appointment of Andrew Hider as president and CEO, effective no later than September 3, 2025. Hider previously served as CEO of ATS since 2017, where he led the company's revenues to nearly double and saw stock price more than triple, bringing proven operational excellence to Baxter's transformation.

Baxter Appoints Andrew Hider as President and CEO

Baxter completed the sale of its Kidney Care business, now known as Vantive, to Carlyle for approximately $3.4 billion of net, after-tax proceeds. Vantive launched as a new standalone company building on a 70-year legacy of kidney care leadership and innovation, allowing Baxter to focus on core medical products.

Baxter Completes Sale of Vantive Kidney Care Business to Carlyle

Baxter reported Q4 2024 worldwide sales from continuing operations of approximately $2.75 billion, increasing 1% on a reported basis and 2% on a constant currency basis. The company provided 2025 financial guidance expecting 5-6% sales growth from continuing operations and adjusted earnings of $2.45-$2.55 per diluted share.

Baxter Reports Fourth Quarter and Full Year 2024 Results

José Almeida retired from his executive roles as chair, president and chief executive officer after leading Baxter since 2016. Brent Shafer assumed the role of Chairman and Interim CEO, with the board initiating a comprehensive search for a permanent CEO that resulted in Andrew Hider's appointment.

Baxter CEO Retirement and Leadership Transition

Baxter's Marion, North Carolina facility resumed producing some IV fluids following significant flooding from Hurricane Helene in September 2024. The facility, which produces approximately 60% of U.S. IV fluids, worked to restore full production capacity to address the nationwide shortage and support healthcare providers.

Baxter Marion Facility Resumes IV Fluid Production After Hurricane Helene

Baxter and Carlyle announced a definitive agreement under which Carlyle would acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion. The strategic divestiture allowed Baxter to focus resources on its core medical products and hospital-focused technologies while creating value for shareholders.

Baxter Announces Definitive Agreement to Divest Vantive Kidney Care Segment

Baxter International stock hit a 52-week low after the company reduced its 2025 guidance by 3% at the midpoint, implying a weaker fourth quarter than expected. New management cited ongoing execution issues and the impact of the failed Hill-Rom acquisition, while also cutting the dividend as part of operational restructuring.

Baxter Stock Hits 20-Year Low Amid Operational Challenges

Drs. Donald Baxter and Ralph Falk launched the Don Baxter Intravenous Products Corporation in Los Angeles, becoming the first commercial manufacturer of prepared IV solutions in the United States.

Company Founded

Baxter introduced the Transfuso-Vac blood collection system, a sterile vacuum-type collection and storage unit for blood that revolutionized transfusion medicine.

Transfuso-Vac System Introduced

Baxter introduced the PLASMA-VAC container, which for the first time allowed plasma to be separated from whole blood for storage, a critical advancement for wartime medicine.

PLASMA-VAC Container Launched

Baxter acquired Hyland Laboratories, becoming the first U.S. company to make commercially available human plasma, expanding into biopharmaceuticals.

Entry into Plasma Business

Baxter introduced the first commercially-built kidney dialysis system, pioneering treatment for chronic kidney disease and establishing decades of leadership in renal care.

First Commercial Dialysis System

Baxter's sales totaled $242 million, securing the company a spot on the Fortune 500 list for the first time, demonstrating significant growth and market impact.

Fortune 500 Recognition

Baxter offered continuous ambulatory peritoneal dialysis (CAPD) as an alternative to hemodialysis for kidney failure, providing patients with more flexible treatment options.

Continuous Ambulatory Peritoneal Dialysis

Baxter acquired GAMBRO AB, a global innovator in renal care, significantly expanding its dialysis product portfolio and global market presence.

GAMBRO Acquisition

Baxter completed the spin-off of its bio-pharmaceuticals business as Baxalta, a new public company, allowing Baxter to focus on medical products while creating shareholder value.

Baxalta Spin-off

Baxter completed the acquisition of Hill-Rom for $12.5 billion, expanding its portfolio of hospital-focused offerings including patient monitoring, diagnostics, and connected care technologies.

Hill-Rom Acquisition

Baxter announced the sale of its biopharma solutions business to private equity firms Warburg Pincus and Advent International for $4.25 billion in cash, streamlining operations.

BioPharma Solutions Divestiture

Baxter announced a definitive agreement to divest its Kidney Care segment, to be named Vantive, to Carlyle Group for $3.8 billion, focusing on core medical products business.

Vantive Kidney Care Sale Announced

Hurricane Helene caused significant flooding at Baxter's Marion, North Carolina facility, which produces approximately 60% of U.S. IV fluids, creating a national healthcare supply challenge.

Hurricane Helene Impact

Baxter completed the sale of its Kidney Care business (Vantive) to Carlyle for approximately $3.4 billion of net, after-tax proceeds, with Vantive launching as a standalone company.

Vantive Sale Completed

José Almeida retired from his executive roles as chair, president and CEO after leading Baxter since 2016. Brent Shafer assumed role as Chairman and Interim CEO.

CEO Transition Announced

Baxter appointed Andrew Hider as president and CEO, with responsibilities beginning no later than September 3, 2025. Hider brings proven track record of operational excellence and growth from ATS.

Amgen vs Baxter International

Amgen

About

Baxter International

About

AI Visibility Head-to-Head

Track AI Visibility in Real Time